Results 91 to 100 of about 1,442,988 (353)

Enhancing the Protein Stability of an Anticancer VHH‐Fc Heavy Chain Antibody through Computational Modeling and Variant Design

Advanced Science, EarlyView.
In this study, a computational pipeline is developed to systematically evaluate the conformational stability, disulfide bond reduction state, and aggregation and degradation tendencies of an anticancer VHH‐Fc fusion antibody. Based on the mechanistic insights, antibody variants with enhanced stability and increased yield are successfully designed. This
Yuan Fang, Menghua Song, Tianning Pu, Xiaoqing Song, Kailu Xu, Pengcheng Shen, Ting Cao, Yiman Zhao, Simon Hsu, Dongmei Han, Qiang Huang   +10 more
wiley   +1 more source

STING Agonists and How to Reach Their Full Potential in Cancer Immunotherapy

Advanced Science, EarlyView.
STING agonists show promise in preclinical studies in boosting an anti‐tumor response using the immune system. However, different limitations remain, and future research is needed to better understand how STING activation impacts the tumor microenvironment, identify effective combination strategies, and determine the best tumor types for STING agonist ...
Laura Gehrcken, Christophe Deben, Evelien Smits, Jonas R.M. Van Audenaerde   +3 more
wiley   +1 more source

Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment

Experimental Hematology & Oncology, 2017
HER2-targeted immunotherapy consists of monoclonal antibodies (e.g. trastuzumab, pertuzumab), bispecific antibodies (e.g. MM-111, ertumaxomab) and activated T cells armed with anti-HER2 bispecific antibody (HER2Bi-aATC). Trastuzumab is a classic drug for
Shengnan Yu, Qian Liu, Xinwei Han, Shuang Qin, Weiheng Zhao, Anping Li, Kongming Wu   +6 more
doaj   +1 more source

Sortilin‐Mediated Rapid, Precise and Sustained Degradation of Membrane Proteins via mRNA‐Encoded Lysosome‐Targeting Chimera

Advanced Science, EarlyView.
The study identified sortilin as a promising LTR, enabling targeted degradation of oncogenic proteins through an mRNA‐encoded MedTAC strategy. In a mouse model, MedTACPTK7 reduced PTK7 by up to 80%, extended survival, and showed excellent pharmacokinetics without toxicity, providing a scalable platform for targeted therapies.
Xin Chang, Xinyu Qiu, Xiaoning Tong, Shaoju Gan, Weicheng Yi, Sitao Xie, Xiangsheng Liu, Chao Zuo, Weihong Tan   +8 more
wiley   +1 more source

In Situ Liver Expression of HBsAg/CD3-Bispecific Antibodies for HBV Immunotherapy

Molecular Therapy: Methods & Clinical Development, 2017
Current therapies against hepatitis B virus (HBV) do not reliably cure chronic infection, necessitating new therapeutic approaches. The T cell response can clear HBV during acute infection, and the adoptive transfer of antiviral T cells during bone ...
Robert L. Kruse, Thomas Shum, Xavier Legras, Mercedes Barzi, Frank P. Pankowicz, Stephen Gottschalk, Karl-Dimiter Bissig   +6 more
doaj   +1 more source

Potential Neutralizing Antibodies Discovered for Novel Corona Virus Using Machine Learning [PDF]

arXiv, 2020
The fast and untraceable virus mutations take lives of thousands of people before the immune system can produce the inhibitory antibody. Recent outbreak of novel coronavirus infected and killed thousands of people in the world. Rapid methods in finding peptides or antibody sequences that can inhibit the viral epitopes of COVID-19 will save the life of ...
arxiv  

Targeted Penetrating Motif Engineering of BH3 Mimetic: Harnessing Non‐Canonical Amino Acids for Coinhibition of MCL‐1 and BCL‐xL in Acute Myeloid Leukemia

Advanced Science, EarlyView.
A structure‐guided peptide derived from a non‐canonical amino acid library simultaneously targets MCL‐1 and BCL‐xL to overcome apoptotic resistance in acute myeloid leukemia. Fused with a CXCR4‐binding motif, the engineered peptide exhibits selective intracellular delivery and potent in vivo efficacy, offering a promising therapeutic strategy against ...
Zhe Wang, Ruizhi Lai, Xinpei Wang, Xu Chen, Youjian Zhou, Shengbin Li, Xiaohui Qiu, Zekai Zeng, Jianye Yuan, Jinghuan Mao, Zhidong Chen, Junqing Wang   +11 more
wiley   +1 more source

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies

Journal of Hematology & Oncology, 2021
Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities has become a promising strategy in clinical management of hematologic malignancies.
Zheng Tian, Ming Liu, Ya Zhang, Xin Wang
doaj   +1 more source

Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy

Journal of Cancer Research and Clinical Oncology, 2020
Bispecific antibodies (BsAbs) have emerged as a leading drug class for cancer therapy and are becoming increasingly of interest for therapeutic applications.
Shuyu Huang, Sander M. J. van Duijnhoven, A. Sijts, A. van Elsas   +3 more
semanticscholar   +1 more source

A scDb-based trivalent bispecific antibody for T-cell-mediated killing of HER3-expressing cancer cells

Scientific Reports, 2021
HER3 is a member of the EGF receptor family and elevated expression is associated with cancer progression and therapy resistance. HER3-specific T-cell engagers might be a suitable treatment option to circumvent the limited efficacy observed for HER3 ...
Nadine Aschmoneit, Sophia Steinlein, Lennart Kühl, Oliver Seifert, Roland E. Kontermann   +4 more
doaj   +1 more source